Farringdon Capital, Ltd. Altimmune, Inc. Transaction History
Farringdon Capital, Ltd.
- $242 Billion
- Q4 2024
A detailed history of Farringdon Capital, Ltd. transactions in Altimmune, Inc. stock. As of the latest transaction made, Farringdon Capital, Ltd. holds 25,295 shares of ALT stock, worth $161,129. This represents 0.08% of its overall portfolio holdings.
Number of Shares
25,295Holding current value
$161,129% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding ALT
# of Institutions
204Shares Held
39.7MCall Options Held
1.8MPut Options Held
1.04M-
Black Rock Inc. New York, NY5.32MShares$33.9 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN5.25MShares$33.5 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.43MShares$28.2 Million0.0% of portfolio
-
State Street Corp Boston, MA3.47MShares$22.1 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$17.5 Million1.49% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $312M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...